Novartis Names Karen Hale as Chief Legal and Compliance Officer

Novartis has announced that Karen Hale will take on the expanded role of Chief Legal and Compliance Officer, effective April 14, 2025. In her new capacity, Hale will oversee both Legal and Ethics, Risk & Compliance (ERC), ensuring that the company continues its strong commitment to integrity and regulatory compliance. She will report directly to CEO Vas Narasimhan, M.D., and remain a key member of the Executive Committee of Novartis (ECN). This leadership transition follows the departure of Klaus Moosmayer, current Chief Ethics, Risk & Compliance Officer, who is stepping down to explore new opportunities outside the company.

Hale, who joined Novartis in 2021 as Chief Legal Officer, brings nearly 30 years of legal and compliance expertise in the pharmaceutical industry, including a tenure at AbbVie. Reflecting on his contributions, Moosmayer expressed pride in his work at Novartis, particularly in strengthening the company’s compliance systems and reputation. Narasimhan praised his impactful leadership and expressed confidence in Hale’s ability to drive ethical and compliance excellence. As Novartis continues to navigate an evolving regulatory landscape, Hale's leadership will play a pivotal role in ensuring transparency, trust, and accountability across the organization.